Clinical Anslysis of TAFRO Syndrome.
10.19746/j.cnki.issn.1009-2137.2023.06.042
- Author:
Fei LIU
1
;
Xiao-Fang WEI
1
;
You-Fan FENG
1
;
Yuan FU
1
;
Qiao-Ling CHEN
1
;
Yang CHEN
1
;
Qi-Ke ZHANG
2
Author Information
1. Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China,E-mail:zqk05@ 163.com.
- Publication Type:Journal Article
- Keywords:
TAFRO syndrome;
cyclophosphamide;
pomalidomide
- MeSH:
Humans;
Thrombocytopenia;
Retrospective Studies;
Castleman Disease/diagnosis*;
Dexamethasone;
Cyclophosphamide/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(6):1872-1877
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics, diagnosis, and treatment of one patient with TAFRO syndrome, and to strengthen the understanding of this rare type.
METHODS:The clinical manifestations, diagnosis and treatment process, and prognosis of the patient admitted in Gansu Provincial People's Hospital were retrospectively analyzed.
RESULTS:Combined with laboratory tests, bone marrow examination, imaging, pathology, etc, the patient was diagnosed with TAFRO syndrome. After three cycles of treatment with pomalidomide (2-3 mg/d, d1-21), cyclophosphamide (300 mg/m2, 0.54 g once a week) and dexamethasone (20 mg/d, two days a week), platelet count, serum creatinine and procalcitonin returned to normal, the systemic edema disappeared, and the patient's condition was alleviated. The therapeutic effect was good.
CONCLUSION:TAFRO syndrome is rare, involves multiple systems, progresses rapidly, and has a worse prognosis. The choice of the "Pomalidomide+cyclophosphamide+dexamethasone" regimen is help to improve the survival prognosis of patient with TAFRO syndrome.
